Mefenamic acid bioequivalence assessment with a new statistical procedure

Pharmacological Research

Volumn 34, Issue 3-4, 1996, Pages 149-152

  Rescigno, A ^a   Marzo, A ^b   Thyroff Friesinger, U ^c  

^a UNIVERSITY OF PARMA   (Italy)

^b IPAS   (United States)

^c Sandoz Biopharmaceuticals   (Germany)

Author keywords

Bioequivalence; Bioequivalence statistics; Confidence intervals; Mefenamic acid

Indexed keywords

MEFENAMIC ACID;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL MODEL;

EID: 0030240329     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1996.0080     Document Type: Article

References (13)

1. 1. Investigation on Bioavailability. Official Journal of the European Community, 1987; 30: 22-9.
2. 2. Note for Guidance: Investigation of Bioavailability and Bioequivalence. CPMP working party on efficacy of medicinal products, III/54/89-EN-FINAL, 1991.
3. 3. Notice to Applicants for marketing authorization for medicinal products for human use in the member states of the European Community. Commission of the European Communities, Vol. II A, 1993.
4. 4. U.S. Food and Drug Adminstration. Bioavailability and Bioequivalence Requirements. Federal Register 1977; 42: 1638-53.
5. 5. Balant LP, Benet LZ, Blume H, Bozler G, Breimer DD, Eichelbaum M, Gundert-Remy U, Hirtz JL, Mutschler E, Midha KK, Rauws AG, Ritschel WA, Sansom LN, Skelly JP, Vollmer KO. Is there a need for more precise definition of bioavailability? Eur J Clin Pharmacol 1991; 4: 123-6.
6. 6. Marzo A, Balant LP. Bioequivalence. An Updated Reappraisal addressed to Application of Interchangeable multi-source Pharmaceutical products. Arzneimittel-Forschung 1995; 45: 109-15.
7. 7. Marzo A, Rescigno A. Pharmacokinetics of endogenous substances: Some problems and some solutions. Eur J Drug Metab Pharmacokinet 1993; 18: 77-88.
8. 8. Rescigno A. Bioequivalence. Pharm Res 1992; 9: 925-8.
9. 9. Westlake WJ. Statistical aspects of comparative bioavailability trials. Biometrics 1979. 35: 273-80.
10. 10. Spriet A, Beiler D. Table to facilitate determination of symmetrical confidence intervals in bioavailability trials with Westlake's method. Eur J Drug Metab Pharmacokinet 1978; 2: 124-32.
11. 11. Shuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-80.
12. 12. Metzler CM. Equivalence of bioavailability and efficacy in drug testing. In: Pecile A, Rescigno A, eds. Pharmacokinetics: mathematical and statistical approaches to metabolism and distribution of chemicals and drugs. New York: Plenum Press: 1988: 215-25.
13. 13. Steinijans VW, Hauschke D. International Harmonization of Regulatory Bioequivalence Requirements. Clin Res Reg Affairs 1993; 10: 203-20.